Vertex Pharmaceuticals (VRTX) Stock Price, Quote, News & History | Benzinga

Vertex Pharmaceuticals Inc (VRTX) Stock Price, Quote, News & History

VRTXNASDAQ

Trade with Public

Trade with Public

$550.39

3.100.57%

Last update: Aug 27, 11:19 AM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$541.74

Close

-

Volume / Avg.

187.91K / 1.51M

Day Range

$540.40 - $550.83

52 Wk Range

374.17 - 555.69

Market Cap

$139.50B

P/E Ratio

31.87

Dividend Yield

-

Exchange

NASDAQ

RSI

66

Short Interest

1.85%

Days to Cover

3.09

Recent Vertex Pharmaceuticals Incorporated News

Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’

CNBC's Halftime Report Final Trades: Sechan picked ServiceNow (NYSE: NOW), Lebenthal chose Vertex (NASDAQ: VRTX) and Brown recommended Uber (NYSE: UBER).

Avi Kapoor

Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday

U.S. stock futures up, focus on earnings from Tyson Foods, Marriott, Universal Logistics, Williams Companies, and Vertex Pharmaceuticals.

Avi Kapoor

Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone

CNN Money Fear & Greed index improved while remaining in 'Fear' zone on Friday. Amazon up 15%, Apple down 7%.

Avi Kapoor

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.

Piero Cingari

Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’

The Halftime Report Final Trades featured stock picks from Bryn Talkington, Jim Lebenthal, Liz Young Thomas, and Joseph M. Terranova.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

4.29B

Investing Cash Flow (TTM)

-882.80M

Financing Cash Flow (TTM)

-2.20B

Free Cash Flow (TTM)

3.80B

Capital Expenditure (TTM)

-496.80M

Net Change in Cash (TTM)

1.21B

Analyst Trends and Forecast

8

Mar

1

Apr

4

May

3

1

Jul

4

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$132.84B

PE Ratio (TTM)

31.87

PE Ratio (FWD)

28.99

PEG Ratio (TTM)

1.90

PS Ratio (TTM)

11.14

PB Ratio (TTM)

6.85

Earnings Yield % (TTM)

3.14%

Earnings Yield % (FWD)

3.45%

EV / EBITDA (TTM)

26.04

Price / EBITDA (TTM)

27.49

Price / Free Cash Flow (TTM)

36.94

Book Value / Share

$79.89

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$6.14B

Debt to Equity

0.10

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$541.74

Close

-

Volume / Avg.

187.91K / 1.51M

Day Range

$540.40 - $550.83

52 Wk Range

374.17 - 555.69

Market Cap

$139.50B

P/E Ratio

31.87

Dividend Yield

-

Exchange

NASDAQ

RSI

66

Short Interest

1.85%

Days to Cover

3.09

About

Sector

Health Care

Industry

Biotechnology

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, whe...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Vertex Pharmaceuticals (VRTX) stock?

A

You can purchase shares of Vertex Pharmaceuticals (NASDAQ:VRTX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Vertex Pharmaceuticals (VRTX) competitors?

A

Other companies in Vertex Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and argenx SE (NASDAQ:ARGX).

Q

What is the forecast, or price target, for Vertex Pharmaceuticals (VRTX) stock?

A

Vertex Pharmaceuticals has a consensus price target of $540.10.

Q

What is the current price for Vertex Pharmaceuticals (VRTX)?

A

The stock price for Vertex Pharmaceuticals (NASDAQ: VRTX) is $550.39 last updated August 27, 2026 at 11:19 AM EDT.

Q

Does Vertex Pharmaceuticals (VRTX) pay a dividend?

A

There are no upcoming dividends for Vertex Pharmaceuticals.

Q

When is Vertex Pharmaceuticals (NASDAQ:VRTX) reporting earnings?

A

Vertex Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Vertex Pharmaceuticals (VRTX) going to split?

A

There is no upcoming split for Vertex Pharmaceuticals.

Q

What sector and industry does Vertex Pharmaceuticals (VRTX) operate in?

A

Vertex Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.